Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up
Open Access
- 29 November 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 26 (2) , 137-144
- https://doi.org/10.1093/eurheartj/ehi010
Abstract
Aims We aimed to evaluate the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) with coronary artery disease (CAD) risk factors, with the severity of angiographic CAD, and with the incidence of major adverse events. Methods and results We measured Lp-PLA2 levels in 504 consecutive patients undergoing clinically indicated coronary angiography. Mean age was 60±11 years and 38% were women. The mean (±SD) Lp-PLA2 level (ng/mL) was 245±91. Lp-PLA2 levels correlated with male gender, LDL, HDL, and total cholesterol, fibrinogen, and creatinine. Lp-PLA2 levels correlated with the extent of angiographic CAD on univariate but not on multivariable analysis. During a median follow-up of 4.0 years, 72 major adverse events occurred in 61 of 466 (13%) contacted patients (20 deaths, 14 myocardial infarctions, 28 coronary revascularizations, and 10 strokes). Higher Lp-PLA2 levels were associated with a greater risk of events: the hazard ratio per SD was 1.28 (95% CI 1.06–1.54, P=0.009), and remained significant after adjusting for clinical and lipid variables and C-reactive protein. Conclusion Higher Lp-PLA2 levels were associated with a higher incidence of major adverse events at follow-up, independently of traditional CAD risk factors and C-reactive protein.Keywords
This publication has 11 references indexed in Scilit:
- Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) StudyCirculation, 2004
- Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolaseAtherosclerosis Supplements, 2002
- C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with anginaJournal of the American College of Cardiology, 2002
- A prospective evaluation of lipoprotein-associated phospholipase A2levels and the risk of future cardiovascular events in womenJournal of the American College of Cardiology, 2001
- Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic targetCurrent Opinion in Pharmacology, 2001
- Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart DiseaseNew England Journal of Medicine, 2000
- Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery diseaseAtherosclerosis, 2000
- Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitorBiochemical Journal, 1999
- Purification, Properties, Sequencing, and Cloning of a Lipoprotein-Associated, Serine-Dependent Phospholipase Involved in the Oxidative Modification of Low-Density LipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 1996